Liraglutide suppressed cholangiocarcinoma cell migration and reduced tumor growth in mice by inhibiting epithelial-mesenchymal transition and Akt/STAT3 signaling, while GLP-1R expression was linked to poorer tumor grade.
Tumor volume reducedliraglutide significantly reduced CCA xenograft tumor size (P=0.046)
What the researchers found
Liraglutide suppressed CCA cell migration and reduced xenograft tumor volumes by inhibiting EMT and Akt/STAT3 phosphorylation, despite GLP-1R expression being associated with poorer histological grade.
Why it matters
With millions of diabetic patients now on GLP-1 agonists, understanding their effects on cancer is critical. This study suggests liraglutide may have anti-tumor effects on bile duct cancer, a notoriously difficult malignancy with few treatment options.
The numbers in context
GLP-1R expression significantly associated with poor histological grading (P = 0.027). Two iCCA cell lines tested (KKU-055 and KKU-213A).
How the study worked
Immunohistochemistry of GLP-1R in human CCA tissues, in vitro proliferation and migration assays in CCA cell lines (KKU-055, KKU-213A) with exendin-4 and liraglutide, and in vivo xenograft mouse tumor models.
Who was studied
Human bile duct cancer tissue samples, iCCA cell lines, and animal tumor models
What this study cannot tell us
Cell line studies may not represent all CCA subtypes; xenograft mice are immunocompromised (may not reflect immune-competent tumor responses); limited sample sizes; only liraglutide and exendin-4 tested; human clinical validation needed; GLP-1R as both risk marker and treatment target creates paradox.
How to read the evidence
Preliminary preclinical evidence from cell lines and mouse xenografts. Interesting and novel but requires human clinical investigation.
When this study was published
Published in 2024, contributing to the evolving understanding of GLP-1 agonists' effects on cancer biology.
The bigger picture
The relationship between GLP-1 agonists and cancer is complex and controversial. This study adds evidence that liraglutide may actually slow certain cancers, which could influence treatment decisions for diabetic patients with CCA risk factors.
Questions still open
- Does the paradox of GLP-1R marking poor grade but liraglutide being protective suggest receptor-independent effects?
- Would liraglutide benefit diabetic patients at risk for cholangiocarcinoma?
- Does GLP-1R downregulation limit long-term anti-tumor efficacy?
Common questions
Could GLP-1 drugs like liraglutide help fight bile duct cancer?
Should cancer patients worry about taking GLP-1 medications?
Read the original research
Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.
Scientific reports, 14(1), 13726
Citation
Trakoonsenathong, Ronnakrit; Kunprom, Waritta; Aphivatanasiri, Chaiwat; Yueangchantuek, Padcharee; Pimkeeree, Paslada; Sorin, Supannika; Khawkhiaw, Kullanat; Chiu, Ching-Feng; Okada, Seiji; Wongkham, Sopit; Saengboonmee, Charupong. (2024). Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.. Scientific reports, 14(1), 13726. https://doi.org/10.1038/s41598-024-64774-2